Project Grant R01CA300038
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $709,677 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 5, 2026, with a completion date of May 31, 2031. The award funds development of quantitative multiparametric Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) magnetic resonance (MR) imaging to improve treatment planning for partial gland ablation of prostate...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Cedars-Sinai Medical Center a $646,784 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 16, 2026, with a completion date of May 31, 2031. This research initiative examines the impact of exogenous hormone use on prostate cancer risk, detection, and outcomes within the Veterans Affairs Health System (VAHS). The project builds on prior published findings indicating that men taking...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $695,634 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded May 7, 2026, with completion targeted for April 30, 2031. The award supports research investigating the role of interleukin-27 (IL-27) cytokine signaling and B cell immune responses in hepatocellular carcinoma (HCC) development and progression. The research addresses a critical clinical need, as...
- Award Summary Cedars-Sinai Medical Center received a $743,264 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded on June 23, 2026, with a completion date of May 31, 2031. The grant funds research integrating high-resolution elemental imaging with spatial transcriptomics to analyze metal-based pathways in tumor growth and metastasis. The project addresses a critical gap in understanding dynamic interactions within...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $662,610 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective April 1, 2026 through March 31, 2031. The award funds research to develop universal methylated circulating tumor DNA (ctDNA) markers for minimal residual disease (MRD) detection and therapy response prediction in colorectal cancer (CRC). The project addresses critical gaps in...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $191,700 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2025 through August 31, 2028. This award supports research investigating the etiology and tumor characteristics of early-onset pancreatic cancer. The project delivers two primary research products: (1) epidemiological analysis identifying modifiable risk factors associated with...
- Award Summary Cedars-Sinai Medical Center received a $708,990 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded May 1, 2026, with a completion date of April 30, 2031. The award funds research investigating how interleukin-17 (IL17) cytokine signaling regulates the tumor microenvironment in colorectal cancer (CRC) liver metastasis. The research employs genetic models of IL17 receptor deficiency, IL17 cytokine neutralization,...
- Grant Award Summary Cedars-Sinai Medical Center received an $858,798 project grant award dated August 18, 2025, from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to investigate extracellular vesicle (EV)-enclosed circular RNA (circRNA) mechanisms in prostate cancer immunosuppression. The award, scheduled for completion by July 31, 2027, supports a two-principal-investigator research effort examining how tumor-associated macrophages (TAMs) become...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $523,670 project grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate an artificial intelligence (AI) model for early detection of pancreatic ductal adenocarcinoma (PDAC) in abdominal computed tomography (CT) scans. The award, obligated on September 12, 2025, with a completion date of August 31, 2029, funds research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $825,627 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of California, Los Angeles, effective May 1, 2026, through April 30, 2031. The award funds development of advanced artificial intelligence models to improve breast cancer prognosis and survival prediction by integrating whole slide image (WSI) pathology data with traditional clinical prognostic factors. The...
Cedars-Sinai Medical Center received a $574,557 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded June 15, 2026, with completion targeted for May 31, 2031. The project integrates life expectancy (LE) estimates into electronic health record (EHR) decision support systems for men with prostate cancer. The research addresses a significant clinical need, as life expectancy is the primary triage factor in prostate cancer treatment guidelines and directly influences treatment selection, yet many clinicians lack readily accessible LE data. The deliverables include development and implementation of LE-integrated clinical decision support tools designed to improve treatment decision-making for men with localized prostate cancer and limited life expectancy—a substantial population comprising approximately one-third of men over 65 and one-half of men over 75 newly diagnosed with prostate cancer. The project focuses on translating prognostic evidence into actionable clinical tools that identify patients best served by observation rather than aggressive treatment, thereby reducing unnecessary morbidity and improving treatment effectiveness. As a leading academic medical center with extensive NIH portfolio experience across oncology and clinical research, Cedars-Sinai will deliver functional EHR decision support capabilities grounded in cancer prevention and risk stratification methodologies aligned with NCI research priorities.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $574.6k | 6/23/26 |